In this session, Nidhi Srivastava, CEO, DigiArmorX, ex-Deutsche Bank, talks on cybersecurity, scope for MBAs and others.

Meta is laying off nearly 8,000 employees globally while pouring up to $145 billion into AI infrastructure. From hiring freezes to AI-focused teams, the company’s latest move shows

Reliance Industries Ltd. is in talks with Chinese battery giant CATL and other global suppliers to procure parts for battery energy storage systems

The US Department of Justice dropped all criminal charges against Gautam Adani, bringing the high-profile alleged bribery case to an end.

The Supreme Court has refused to dilute its earlier order on removing stray dogs from public spaces like hospitals, schools and railway stations.

Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of levothyroxine sodium tablet indicated as a replacement therapy for hypothyroidism.
The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of levothyroxine sodium tablets of strengths 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, Alembic said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the reference listed drug product, Synthroid tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, of AbbVie, Inc, it added.
Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, the company said.
Levothyroxine sodium tablets are indicated as .

Alembic Pharmaceuticals (Photo: Company website)

Press Trust of India

The urgency has grown after the rupee slumped to a record low of nearly 97 per dollar this week, driving up import costs and further eroding investors' confidence

Reserve Bank of India, RBI

Bloomberg

Max Healthcare reported a consolidated revenue from operations of ₹2,142.89 crore, up 12.2 per cent from ₹1,909.74 crore in the year-ago period

Max Healthcare

Business Standard

RITES Ltd, an infrastructure, consultancy and engineering firm, on Tuesday reported a 2 per cent drop in net profit at Rs 129.97 crore for March quarter FY26 impacted by higher expenses.
The company had posted a net profit of Rs 132.71 crore for the year-ago period.
However, income during the January-March period rose to Rs 799.21 crore over Rs 625.81 crore in the year-ago period, RITES said in a filing to BSE.
Expenses too increased to Rs 617.50 crore from Rs 434.76 crore.
The board has recommended final dividend of Rs 2.75 per share for financial year 2025-26, subject to approval by shareholders.
The company is into various segments including railways, metros, tunnels, bridge, urban engineering, sustainability and green mobility, airports and institutional buildings.

Q4, Q4 results

The win has also pushed RR ahead in the race to the playoffs as they now just need to win their last game against Mumbai Indians (MI) on May 24 to finish in the top four

IPL 2026 RR vs LSG full scorecard

The venue, home to IPL franchise Chennai Super Kings, has emerged as the frontrunner after months of discussions involving Cricket Australia, the BCCI, and the Tamil Nadu Cricket Association

BBL 2025-26 champions Perth Scorchers

Four institutional initiatives could materially accelerate the investment surge needed for the next phase of growth

Financing India’s structural transformation

Parle Industries came into limelight on Wednesday after Italian Premier Giorgia Meloni shared a video of Prime Minister Narendra Modi gifting her a packet of Melody toffees.

PM Narendra Modi with Italian counterpart Giorgia Meloni

The Centre argued before the Supreme Court that the Rs 8,415-crore AT1 bond write-down was necessary to protect depositors and preserve financial stability

Yes Bank

On its first day in theatres, Mohanlal's Drishyam 3 made a robust Rs 43 crore worldwide. As of 1 pm on its day 2, the movie reportedly made Rs 5 crore. On May 21, the movie opened in theatres

Drishyam 3 OTT release

BS Rich Content

Find X9 Ultra builds on OPPO's already strong camera foundation with better consistency, improved zoom, and more natural output, making it one of the most capable camera-focused smartphones right now

Oppo Find X9 Ultra in Canyon Orange colour

AI referrals are beginning to show up in web traffic data, but remain marginal as search, direct and social channels continue to dominate discovery despite rising adoption of AI tools

Please Enter some text in above box to get result

Latest News

In this section

All

Drishyam 3 Box office collection Day 1: Mohanlal eyes Rs 50 cr worldwide

OPPO Find X9 Ultra review: The most complete camera flagship smartphone

AI-led discovery grows, but search continues to drive web traffic: Report

Most Popular

Read

Shared

Commented

Alembic Pharma gets USFDA nod for generic levothyroxine sodium tablets

RBI may turn to 2013 taper tantrum playbook to defend weakening rupee

Max Healthcare falls 7% on Q4 results; profit rises 7% amid margin pressure

Also Watch

Please Enter some text in above box to get result Advance Search